APEX1 and cancer: Because APE1 is known to be phosphorylated [65], it is possible that such modification of APE1 in cancer cells enhances its interaction with p300 to induce acetylation or decrease its interaction with HDAC1/SIRT1 to maintain enhanced level of APE1 acetylation.